La plupart des derniers articles sont réalisés en partie grâce à vos dons et notre Association est remerciée


- Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. Lung Cancer. 2023 Volume 185.

- Boisgerault N, Bertrand P.Inside PD-1/PD-L1,2 with their inhibitors. Eur J Med Chem. 2023 Aug 5;256:115465. doi: 10.1016/j.ejmech.2023.115465. Epub 2023 May 6. PMID: 37196547.


-  Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C. ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Front Immunol. 2023 Jul 19;14:1196731. doi: 10.3389/fimmu.2023.1196731. eCollection 2023.


- Grard M, Idjellidaine M, Arbabian A, Chatelain C, Berland L, Combredet C, Dutoit S, Deshayes S, Dehame V, Labarrière N, Fradin D, Boisgerault N, Blanquart C, Tangy F, Fonteneau JF.Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. Cancer Immunol Immunother. 2023 Jul 19.



- Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clin Res Rep. 2022 Nov 7;3(12):100430.

- Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Sallé F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Mol Oncol. 2022 Nov 30. doi: 10.1002/1878-0261.13351.

- Hariharan A, Qi W, Rehrauer H, Wu L, Ronner M, Wipplinger M, Kresoja-Rakic J, Sun S, Oton-Gonzalez L, Sculco M, Serre-Beinier V, Meiller C, Blanquart C, Fonteneau JF, Vrugt B, Rüschoff JH, Opitz I, Jean D, de Perrot M, Felley-Bosco E. Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment. Mol Oncol. 2022 Oct 11. doi: 10.1002/1878-0261.13322.

- Mai HL, Deshayes S, Nguyen TV, Dehame V, Chéné AL, Brouard S, Blanquart C. IL-7 is expressed in malignant mesothelioma and has a prognostic value. Mol Oncol. 2022 Oct;16(20):3606-3619. doi: 10.1002/1878-0261.13310.

- Blondy T, Poly J, Linot C, Boucard J, Allard-Vannier E, Nedellec S, Hulin P, Hénoumont C, Larbanoix L, Muller RN, Laurent S, Ishow E and Blanquart C. Impact of RAFT chain transfer agents on the polymeric shell density of magneto-fluorescent nanoparticles and their cellular uptake. 2022. Nanoscale. 14(15):5884-5898.

- Marazioti A, Krontira AC, Behrend SJ, Giotopoulou GA, Ntaliarda G, Blanquart C, Bayram H, Iliopoulou M, Vreka M, Trassl L, Pepe MAA, Hackl CM, Klotz LV, Weiss SAI, Koch I, Lindner M, Hatz RA, Behr J, Wagner DE, Papadaki H, Antimisiaris SG, Jean D, Deshayes S, Grégoire M, Kayalar Ö, Mortazavi D, Dilege Ş, Tanju S, Erus S, Yavuz Ö, Bulutay P, Fırat P, Psallidas I, Spella M, Giopanou I, Lilis I, Lamort AS, Stathopoulos GT. KRAS signaling in malignant pleural mesothelioma. 2022. EMBO Mol Med. 13:e13631.



- Grard M, Chatelain C, Delaunay T, Pons-Tostivint E, Bennouna J, Fonteneau JF. 2021.  Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Front Oncol. 11:695770.

- Lavy M, Gauttier V, Poirier N, Barillé-Nion S, Blanquart C. 2021. Specialized Pro-Resolving Mediators Mitigate Cancer-Related Inflammation: Role of Tumor-Associated Macrophages and Therapeutic Opportunities. Front Immunol. Jun 30;12:702785.

- Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. 2021. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer. 20(1):55.

- Sun S, Frontini F, Qi W, Hariharan A, Ronner M, Wipplinger M, Blanquart C, Rehrauer H, Fonteneau JF, Felley-Bosco E. 2021. Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development. Cancer Lett. 10:S0304-3835(21)00108-7.

- Soamalala J, Diot S, Pellerano M, Blanquart C, Galibert M, Jullian M, Puget K, Morris MC. 2021. Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts. Chembiochem. 22(6):1065-1071.



- Petithomme T, Grard M, Fonteneau JF, Boisgerault N. Le vaccin contre la fièvre jaune : un nouveau traitement anti-tumoral ? Médecine/Sciences. 2020 Dec;36(12):1216-1217.

 - Delaunay T, Nader J, Grard M, Farine I, Hedwig V, Foloppe J, Blondy T, Violland M, Pouliquen D, Grégoire M, Boisgerault N, Erbs P, Fonteneau JF. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma. Molecular Therapy Oncolytics. 2020 Aug 25;18:573-578.

 - Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest. 2020. 130(11):6109-6123.

- Kara-Terki L, Treps L, Blanquart C, Fradin D. Critical Roles of Tumor Extracellular Vesicles in the Microenvironment of Thoracic Cancers. Int J Mol Sci. 2020. 21(17):E6024.

- Jean D, Delaunay T, Meiller C, Boisgerault N, Grard M, Caruso S, Blanquart C, Felley-Bosco E, Bennouna J, Tangy F, Grégoire M, Fonteneau JF. Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. J Thorac Oncol. 2020. 15(7):e113-e116.

- Blondy T, d’Almeida SM, Briolay T, Tabiasco J, Meiller C, Chéné AL, Cellerin L, Deshayes S, Delneste Y, Fonteneau JF, Boisgerault N, Bennouna J, Grégoire M, Jean D, Blanquart C. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma. J Immunother Cancer. 2020. 8(1):e000182.

- Blanquart C, Jaurand MC, Jean D. The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models. Front Oncol. 2020. 25;10:388

- Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF. Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thorac Oncol. 2020. 15(5):827-842.

- Delaunay T, Achard C, Grégoire M, Tangy F, Boisgerault N, Fonteneau JF. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death. Methods Mol Biol. 2020. 2058:127-132.

- Marotte L, Simon S, Vignard V, Dupré E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Schaffer J, Fradin D, Jarry A, N’Guyen T, Labarrière N. Increased anti-tumor efficacy of Human PD-1 deficient Melanoma-specific Lymphocytes. J ImmunoTher Cancer. 2020. 8(1). pii: e000311.

- Vanbervliet-Defrance B, Delaunay T, Daunizeau T,  Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M,  Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF,  Lebecque S, Mahtouk K. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. Cancer Letters. 2020. 1;472:29-39.



- Bertrand P*, Blanquart C*, Héroguez V*. The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy. Biomolecules. 2019. 12;9(2).

- Bouchet S, Linot C, Ruzic D, Agbaba D, Fouchaq B, Roche J, Nikolic K, Blanquart C, Bertrand P. Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Med Chem Lett. 2019. 10(6):863-868.

- Boucard J, Briolay T, Blondy T, Boujtita M, Nedellec S, Hulin P, Grégoire M, Blanquart C*, Ishow E*. Hybrid Azo-fluorophore Organic Nanoparticles as Emissive Turn-on Probes for Cellular Endocytosis. ACS Appl Mater Interfaces. 2019. 11(36):32808-32814.

- Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic metalloenzymes. Curr Med Chem. 2019. 26(15):2748-2785.



- Smeele P, d’Almeida SM, Meiller C, Chéné AL, Liddell C, Cellerin L, Montagne F, Deshayes S, Benziane S, Copin MC, Hofman P, Le Pimpec-Barthes F, Porte H, Scherpereel A, Grégoire M, Jean D and Blanquart C. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. Mol Cancer. 2018. 17(1):148.

- Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C. p53 regulates CD46 expression and measles virus infection in myeloma cells. Blood Adv. 2018. 11;2(23):3492-3505.

- Hladíková K, Partlová S, Koucký V, Bouček J, Fonteneau JF, Zábrodský M, Tachezy R, Grega M, Špíšek R, Fialová A. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. Oral Oncol. 2018. 82:75-82.

- Vidakovic M, Marinello J, Lahtela-Kakkonen M, Matulis D, Linkuvienė V, Michel BY, Navakauskienė R, Christodoulou MS, Passarella D, Klimasauskas S, Blanquart C, Cuendet M, Ovadi J, Poulain S, Fontaine-Vive F, Burger A, Martinet N.. New Insights into the Epigenetic Activities of Natural Compounds. OBM Genetics. 2018. 2(3):029.

- Boucard J, Linot C, Blondy T, Nedellec S, Hulin P, Blanquart C*, Lartigue L, Ishow E*. Small Molecule-Based Fluorescent Organic Nanoassemblies with Strong Hydrogen Bonding Networks for Fine Tuning and Monitoring Drug Delivery in Cancer Cells. Small. 2018. 14(38):e1802307.

- Vignard V and Fradin D. Non-coding RNAs in Cutaneous Melanoma Development, Progression and Dissemination. OBM Genetics. 2018. 2 (2), p1 10.21926/obm.genet.1802020. Review.

- Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clinical Epigenetics. 2018. 10:79.

- Le Stunff C, Castell AL, Todd N, Mille C, Belot MP, Frament N, Brailly-Tabard S, Benachi A, Fradin D, Bougnères P. Fetal growth is associated with CpG methylation in the P2 promoter of the IGF1 gene. Clin Epigenetics. 2018 Apr 19;10:57.

- Nader JS, Abadie J, Deshayes S, Boissard A, Blandin S, Blanquart C, Boisgerault N, Coqueret O, Guette C, Grégoire M, Pouliquen DL. Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma. Oncotarget. 2018. 27;9(23):16311-16329.



- Linot C, Poly J, Boucard J, Pouliquen D, Nedellec S, Hulin P, Marec N, Arosio P, Lascialfari A, Guerrini A, Sangregorio C, Lecouvey M, Lartigue L, Blanquart C*, Ishow E*. PEGylated Anionic Magnetofluorescent Nanoassemblies: Impact of Their Interface Structure on Magnetic Resonance Imaging Contrast and Cellular Uptake. ACS Appl Mater Interfaces. 2017. 26;9(16):14242-14257.

- Ben-Avraham D, Govindaraju DR, Budagov T, Fradin D, Durda P, Liu B, Ott S, Gutman D, Sharvit L, Kaplan R, Bougnères P, Reiner A, Shuldiner AR, Cohen P, Barzilai N, Atzmon G. The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature. Sci Adv. 2017. 16;3(6):e1602025.

- Fradin D, Boëlle PY, Belot MP, Lachaux F, Tost J, Besse C, Deleuze JF, De Filippo G, Bougnères P. Genome-Wide Methylation Analysis Identifies Specific Epigenetic Marks In Severely Obese Children. Sci Rep. 2017.7;7:46311.

 - Belot MP, Nadéri K, Mille C, Boëlle PY, Benachi A, Bougnères P, Fradin D. Role of DNA methylation at the placental RTL1 gene locus in type 1 diabetes. Pediatr Diabetes. 2017. 18(3):178-187.

- Boisgerault N, Grégoire M, Fonteneau JF.Viral cancer therapies: are they ready for combination with other immunotherapies?  Future Oncol. 2017. 13(18):1569-1571.

- Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R. Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. Cancer Immunol Res. 2017. 5(11):1029-1045.

- Simon T, Pogu J, Rémy S, Brau F, Pogu S, Maquigneau M, Fonteneau JF, Poirier N, Vanhove B, Blancho G, Piaggio E, Anegon I, Blancou P. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers. J Autoimmun. 2017. 81:44-55.

- Delaunay T, Violland M, Boisgerault N, Dréno B, Labarrière N, Bell JC, et al. Oncolytic viruses sensitize tumor cells for NYESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology. 2017. 26;7(3):e1407897.

- Allagui F, Achard C, Panterne C, Combredet C, Labarrière N, Dréno B, Elgaaied AB, Pouliquen D, Tangy F, Fonteneau JF, Grégoire M, Boisgerault N. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus. Curr Gene Ther. 2017. 16(6):419-428.

- Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Grégoire M and Fonteneau JF. Oncolytic measles virus induces Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology. 2017. 26;7(3):e1407897



- Chéné AL, d'Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau JF, Cellerin L, Delneste Y, Grégoire M, Blanquart C. Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages. J Thorac Oncol. 2016. 11(10):1765-73.

- Ouni M, Belot MP, Castell AL, Fradin D, Bougnères P. The P2 promoter of the IGF1 gene is a major epigenetic locus for GH responsiveness. Pharmacogenomics J. 2016. 16(1):102-6.

- Roulois D, Deshayes S, Guilly MN, Nader J, Liddell C, Robard M, Hulin P, Ouacher A,  Le Martelot V, Fonteneau JF, Grégoire M, Blanquart C* and  Pouliquen DL*. Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine. Oncotarget. 2016. 7(23):34664-87.

- El Bahhaj F£, Denis I£, Pichavant L, Delatouche R, Collette F,  Linot C, Pouliquen D, Grégoire M, Héroguez V, Blanquart C*, Bertrand P*. Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy. Theranostics. 2016. 6(6): 795-807.

- Zwick V, Nurisso A, Simões-Pires C, Bouchet S, Martinet N, Lehotzky A, Ovadi J, Cuendet M, Blanquart C, Bertrand P. Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. Bioorg Med Chem Lett. 2016. 26(1):154-9.

- Fonteneau JF, Brilot F, Münz C, Gannage M. The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer. Journal of Immunology. 2016. 196(1):64-71.



- Denis I, El Bahhaj F, Collette F, Delatouche R, Gueugnon F, Pouliquen D, Pichavant L, Héroguez V, Grégoire M, Bertrand P, Blanquart C. Histone deacetylase inhibitor-polymer conjugate nanoparticles for acid-responsive drug delivery. Eur J Med Chem. 2015. 95:369-76.

- Achard C, Boisgerault N, Delaunay T, Roulois D, Nedellec S, Royer PJ, Pain M, Combredet C, Mesel-Lemoine M, Cellerin L, Magnan A, Tangy F, Grégoire M, Fonteneau JF. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Oncotarget. 2015. 6(42):44892-904.

- Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, and Fonteneau JF. Oncolytic virotherapy for human malignant mesothelioma: recent advances. Oncolytic virotherapy. 2015. 4:133-140.

- Fonteneau JF, Achard C, Zaupa C, Foloppe J, and Erbs P. Oncolytic immunotherapy: the new clinical outbreak. Oncoimmunology. 2015. 12;5(1):e1066961

- Peric Z, Cahu X, Malard F, Brissot E, Chevallier P, Guillaume T, Grégoire M, Gaugler B, Mohty M. Peripheral blood plasmacytoid dendritic cells at day 100 can predict outcome after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2015. S1083-8791(15)00232-3.

- Chalopin B, Florenceau L, Fradin D, Labarrière N, Moreau-Aubry A. A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigens. Melanoma Res. 2015. 25(4):279-83

- Ouni M, Gunes Y, Belot MP, Castell AL, Fradin D, Bougnères P.  The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth. Clin Epigenetics. 2015. 7:22. doi: 10.1186/s13148-015-0062-8. eCollection 2015.

- Achard C, Boisgerault N, Delaunay T, Tangy F, Grégoire M, Fonteneau JF. Induction of immunogenic tumor cell death by attenuated oncolytic measles virus. Journal of Clinical and Cellular Immunology. 2015. 6: 291.

- Brissot E, Bossard B, Malard F, Braudeau C, Chevallier P, Guillaume T, Delaunay J, Josien R, Grégoire M, Gaugler B, Mohty M. Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease. Journal of Leukocyte Biology. 2015. 97(2):227-35.



- El Bahhaj F, Désiré J, Blanquart C, Martinet N, Zwick V, Simões-Pires C, Cuendet M, Grégoire M, Bertrand P. Superacid and thiol-ene reactions for access to psammaplin analogues with HDAC inhibition activities. Tetrahedron. 2014. 70:9702-9708

- Christodoulou MS, Thomas A, Poulain S, Vidakovic M, kakkonen ML, Matulis D, Bertrand P, Bartova E, Blanquart C, Mikros E, Fokialakis N, Passarella D, Benhida R and Martinet N. Can we use the epigenetic bioactivity of phytochemicals to promote healthy ageing? Med Chem Comm. 2014. 5:1804-1820. 

- Denis I, El Bahhaj F, Collette F, Delatouche R, Gueugnon F, Pouliquen D, Pichavant L, Héroguez V, Grégoire M, Bertrand P*, and Blanquart C*. Vorinostat−Polymer Conjugate Nanoparticles for Acid-Responsive Delivery and Passive Tumor Targeting. Biomacromolecules. 2014. 15(12):4534-43. 

- Malard F,  Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M. Increased Th17/Treg ratio in liver chronic graft-versus-host-disease. Bone Marrow Transplantation. 2014. 49(4):539-544.

- Deauvieau F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. International Journal of Cancer. 2014. 136(5):1085-94.

- Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. Journal of Immunology. 2014. 192(4):1962-71.

- D. L. Pouliquen. Curcumin. Synthesis, Emerging Role in Pain Management and Health Implications. (ed.), Nova Science Publishers, Inc., New York, NY, USA, 2014. ISBN: 978-1-63321-319-7, 517pp.

- Pouliquen DL, Nawrocki-Raby B, Ouacher A, Deleine C, Blandin S, Robard M, Birembaut P, Grégoire M. New prospects with curcumin in the treatment of mesothelioma: lessons from an orthotopic rat tumor model. In: Curcumin. Synthesis, Emerging Role in Pain Management and Health Implications. D. L. Pouliquen (ed.), Nova Science Publishers, Inc., New York, NY, USA, 2014. ISBN : 978-1-63321-319-7, pp 435-455.

- Zwick V, Chatzivasileiou AO, Deschamps N, Roussaki M, Simões-Pires CA, Nurisso A, Denis I,  Blanquart C, Martinet N, Carrupt PA, Detsi A, and Cuendet M. Aurones as histone deacetylase inhibitors: identification of key features. Bioorg Med Chem Lett. 2014. 24(23):5497-5501. 

- Denis I, Cellerin L, Gregoire M, Blanquart C. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma. Oncotarget. 2014. 5(22):11641-52.

- Gueugnon F, Cartron PF, Charrier C, Bertrand P,  Fonteneau JF, Gregoire M,  and  Blanquart C. New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. Oncotarget. 2014. 30;5(12):4504-15.



- Gueugnon F, Denis I, Pouliquen D, Collette F, Delatouche R, Héroguez V, Grégoire M, Bertrand P, Blanquart C. Nanoparticles produced by ring-opening metathesis polymerization using norbornenyl-poly(ethylene oxide) as a ligand-free generic platform for highly selective in vivo tumor targeting. Biomacromolecules. 2013. 8;14(7):2396-402.

- Delatouche R, Denis I, Grinda M, El Bahhaja F, Baucher E, Collette F, Heroguez V, Grégoire M, Bertrand P*, Blanquart C*. Design of pH responsive clickable prodrugs applied to histone deacetylases inhibitors: a new strategy for anticancer therapy. European Journal of Pharmaceutics and Biopharmaceutics. 2013. 85:862-72.

- Cartron PF, Blanquart C, Hervouet E, Gregoire M and Vallette FM. 2013. HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. Molecular Oncology. 2013. 7(3):452-63.

- Collette F, Delatouche R, Blanquart C, Gueugnon F, Grégoire M, Bertrand P, Héroguez V. Easy and effective method to produce functionalized particles for cellular uptake. Journal of Polymer Science Part A: Polymer Chemistry. 2013. 51:176-189.

- Malard F,  Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M. Increased plasmacytoid dendritic cells and RORt-expressing immune effectors in cutaneous acute graft-versus-host disease. Journal of Leukocyte Biology. 2013. 94(6):1337-1343.

- Simon T, Fonteneau JF, Grégoire M. Requirement of tumor-associated antigens specific CD4+ T cells for efficient dendritic cells vaccine in anti-tumoral immunotherapy. Immunotherapy. 2013. 5(6):1-3.

- Guillerme JB, Grégoire M, Tangy F, Fonteneau JF. Antitumor virotherapy by attenuated measles virus. Biology (Basel). 2013. 2:587-602.

- Fonteneau JF, Guillerme JB, Tangy F, Grégoire M. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology. 2013. 1;2(5):e24212.

- Guillerme JB, Boisgerault N, Roulois D, Ménager J, Combredet C, Tangy F, Grégoire* M, Fonteneau* JF. Measles virus-vaccine infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clinical Cancer Research. 2013. 19:1147-1158.

- Boisgerault N, Guillerme JB, Pouliquen D, Mesel-Lemoine M, Combredet C, Achard C, Fonteneau JF, Tangy F, Grégoire M. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. BioMed Research International (J. Biomed. Biotechnol.). 2013. 387362.

- Roulois D, Grégoire M, Fonteneau JF. MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. BioMed Research International. 2013. 2013:871936.

- Grégoire M. Immunothérapie du mésothéliome. Revue des Maladies Respiratoires Actualités. 2013. 5:221-224.

- Grégoire M, Boisgerault N, Guillerme JB, Fonteneau JF. Le vaccin de la rougeole pour traiter le mésothéliome. La lettre du pneumologue. 2013. XVI(2):72-77.



- Blanquart C *, Gueugnon F *, Nguyen JM, Cellerin L, Sagan C, Perigaud C, Scherpereel A, and Gregoire M. CCL2, Galectin-3 and SMRP combination improves the diagnosis of Mesothelioma in pleural effusions. J Thorac Oncol. 2012. 7(5):883-9.

- Roulois D, Blanquart C, Panterne C, Gueugnon F, Grégoire M, Fonteneau JF. Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Eur J Immunol. 2012. 42(3):783-9.



- Blanquart C, François M, Charrier C, Bertrand P, Gregoire M. Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds. Curr Cancer Drug Targets. 2011. 11(8):919-28.

- Guillot F, Boutin B, Blanquart C, Fonteneau J-F, Robard M, Grégoire M, Pouliquen D. 2011. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine.  2011. 26;29(33):5534-43.

- Leclercq S§, Gueugnon F§, Boutin B, Guillot F, Blanquart C, Rogel A, Padieu M, Pouliquen D, Fonteneau J-F, Gregoire M. 5-aza-2'-deoxycytidine/valproate combination induces CTL response against mesothelioma. Eur Resp J. 2011. 38(5):1105-16.

- Gueugnon F, Blanquart C§, Leclercq S§, Sagan C, Cellerin L, Padieu M, Perigaud C, Scherpereel A, Gregoire M. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol. 2011. 178(3):1033-42.